Article

Stem Cell Reviews and Reports

, Volume 7, Issue 3, pp 693-702

Open Access This content is freely available online to anyone, anywhere at any time.

Induced Pluripotent Stem Cell Lines Derived from Equine Fibroblasts

  • Kristina NagyAffiliated withSamuel Lunenfeld Research Institute, Mount Sinai Hospital
  • , Hoon-Ki SungAffiliated withSamuel Lunenfeld Research Institute, Mount Sinai Hospital
  • , Puzheng ZhangAffiliated withSamuel Lunenfeld Research Institute, Mount Sinai Hospital
  • , Simon LaflammeAffiliated withFaculty of Veterinary Medicine, Centre de Recherche en Reproduction Animale, Universite de Montreal
  • , Patrick VincentAffiliated withFaculty of Veterinary Medicine, Centre de Recherche en Reproduction Animale, Universite de Montreal
  • , Siamak Agha-MohammadiAffiliated withHillman Cancer Center, University of Pittsburgh Medical Center
  • , Knut WoltjenAffiliated withSamuel Lunenfeld Research Institute, Mount Sinai HospitalCenter for iPS Cell Research and Application (CiRA), Institute for Integrated Cell-Material Sciences (iCeMS), Kyoto University
  • , Claudio MonettiAffiliated withSamuel Lunenfeld Research Institute, Mount Sinai Hospital
  • , Iacovos Prodromos MichaelAffiliated withSamuel Lunenfeld Research Institute, Mount Sinai Hospital
    • , Lawrence Charles SmithAffiliated withFaculty of Veterinary Medicine, Centre de Recherche en Reproduction Animale, Universite de Montreal Email author 
    • , Andras NagyAffiliated withSamuel Lunenfeld Research Institute, Mount Sinai HospitalDepartment of Molecular Genetics, University of Toronto Email author 

Abstract

The domesticated horse represents substantial value for the related sports and recreational fields, and holds enormous potential as a model for a range of medical conditions commonly found in humans. Most notable of these are injuries to muscles, tendons, ligaments and joints. Induced pluripotent stem (iPS) cells have sparked tremendous hopes for future regenerative therapies of conditions that today are not possible to cure. Equine iPS (EiPS) cells, in addition to bringing promises to the veterinary field, open up the opportunity to utilize horses for the validation of stem cell based therapies before moving into the human clinical setting. In this study, we report the generation of iPS cells from equine fibroblasts using a piggyBac (PB) transposon-based method to deliver transgenes containing the reprogramming factors Oct4, Sox2, Klf4 and c-Myc, expressed in a temporally regulated fashion. The established iPS cell lines express hallmark pluripotency markers, display a stable karyotype even during long-term culture, and readily form complex teratomas containing all three embryonic germ layer derived tissues upon in vivo grafting into immunocompromised mice. Our EiPS cell lines hold the promise to enable the development of a whole new range of stem cell-based regenerative therapies in veterinary medicine, as well as aid the development of preclinical models for human applications. EiPS cell could also potentially be used to revive recently extinct or currently threatened equine species.

Keywords

Induced pluripotent stem cells iPS cells Equine Horse Transposon Tetracycline inducible Non-viral PiggyBac